-
K-drug single-agent first-line treatment is recommended by CSCO guidelines: A new standard for the treatment of MSI-H/dMMR metastatic colorectal cancer is born
Time of Update: 2021-05-21
An important update of this guideline is to separately list the initial unresectable metastatic colorectal cancer (mCRC) with highly microsatellite instability (MSI-H)/mismatch repair defect (dMMR) gene characteristics, and to give PD-1 Immune checkpoint inhibitor pembrolizumab (commonly known as K drug in China) single-agent first-line treatment recommended by level I experts, level of evidence 1A.
-
Aspirin and ibuprofen can reduce the risk of occurrence and recurrence of advanced colorectal adenomas; ADC drug gosartuzumab is planned to be included in the priority review|Tumor News
Time of Update: 2021-05-21
New drug: ADC drug Gosarturumab will be included in the application for priority review in China to treat triple-negative adult breast cancer 01Gut: No matter Whether Helicobacter pylori is eradicated or not, proton pump inhibitors all increase the risk of gastric cancer.
-
2021 CSCO Guidelines Conference|Professor Zhou Jun: Progress and Prospects of Diagnosis and Treatment of Biliary Tract Malignant Tumors
Time of Update: 2021-05-21
After the meeting, Yimaitong was fortunate to invite Professor Zhou Jun to interpret the new version of the guidelines for the diagnosis and treatment of biliary malignancies, discuss the future research hotspots and development directions of targeted and immunotherapy in the field of biliary malignancies, and share the challenges and solutions for diagnosis and treatment in the field of biliary malignancies.
-
Prof. Jun Ma: Interpreting the updated key points of the guidelines for nasopharyngeal cancer, looking forward to the progress and prospects of antivascular therapy
Time of Update: 2021-05-21
Immunotherapy combined with anti-angiogenesis therapy is one of the current research directions for recurrent and metastatic nasopharyngeal carcinoma, and it is also a treatment with great potential.
-
"Universal" allogeneic CD30-CAR EBVST cell therapy!
Time of Update: 2021-05-21
com" target="_blank">"Universal" T cell therapy (TT11X)TT11X is an allogeneic, CD30 chimeric antigen receptor, and Epstein-Barr virus-specific T cell therapy (allogeneic CD30-CAR EBVST) , which is being jointly developed by Baylor College of Medicine in the United States and Tesha Biology.
-
The Oncologist: The relationship between HER2 gene changes and microsatellite instability (MSI-H) in colorectal adenocarcinoma
Time of Update: 2021-05-21
In the HERACLES and MyPathway clinical trials, the objective response rate (ORR) of anti-HER2 treatment for colorectal cancer patients was 30% and 38%.
Twenty-five patients with MSI-H received PD-1 monoclonal antibody treatment, of which 9 had HER2 mutations and 16 had no HER2 changes.
-
[Nature Magazine] Harvard scientists are exploring the mystery of esophageal cancer and ancient viruses. Blocking the ADAR1 enzyme is so important!
Time of Update: 2021-05-21
The study established a new set of esophageal organoids to show that when the oncogene SOX2 is overactive, it can induce the expression of ancient transcription viruses, thereby making esophageal cancer dependent on the ADAR1 enzyme, providing a new target for cancer treatment.
-
J Thorac Oncol: The efficacy of small cell lung cancer (SCLC) in preventing intracranial irradiation to avoid or not avoid hippocampal structure (HA): a randomized III clinical trial (NCT01780675)
Time of Update: 2021-05-21
Small cell lung cancer (SCLC) prevention of intracranial irradiation without avoiding hippocampal irradiation (HA-PCI) did not lead to a significant decline in neurocognitive function, and the rate of brain metastasis within 2 years did not increase significantly.
-
Is trastuzumab adjuvant therapy for 9 weeks or 1 year?
Time of Update: 2021-05-21
At present, for patients with HER2-positive early breast cancer, 6 to 8 rounds of adjuvant chemotherapy + 1 year trastuzumab have become the standard of adjuvant treatment.
The trial randomly divided 1,254 HER2-positive early breast cancer patients into chemotherapy-adjuvant 9-week trastuzumab group vs 1-year trastuzumab group.
-
Learn these tricks!
Time of Update: 2021-05-21
Journal of Practical Dermatology,2016,9(1):34-37[4] Elderly Expert consensus on diagnosis and treatment of pruritus[J].
Chinese Journal of Dermatology and Venereology,2018,32(11):1233-1236[5]Expert consensus on synergistic treatment of AIDS skin pruritus[J].
Journal 2020,59(10):764-771[14] Recommendations for diagnosis and treatment of adverse skin reactions related to immune checkpoint inhibitors[J].
-
JCO: Phase 3 clinical trial | gemcitabine + cisplatin combined with bevacizumab for the treatment of advanced urothelial carcinoma
Time of Update: 2021-05-21
Blood vesselFrom July 2009 to December 2014, a total of 506 patients with metastatic urothelial cancer who had not received chemotherapy for metastatic lesions and had not received neoadjuvant or adjuvant chemotherapy within 12 months were randomly assigned to GCB Group or GCP group.
-
Lancet oncol: The anti-tumor activity of Cemiplimab in locally advanced basal cell carcinoma is promising
Time of Update: 2021-05-21
1016/S1470-2045(21)00126-1" target="_blank" rel="noopener">Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial .
1016/S1470-2045(21)00126-1" target="_blank" rel="noopener">Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial in this message
-
Lancet: PET-CT assisted postoperative radiotherapy and chemotherapy for prostate cancer can effectively improve the survival rate!
Time of Update: 2021-05-21
Traditional CT and bone scans are not very sensitive to the staging of high-risk prostate cancer patients, so researchers have been investigating the effects of new PET-CT imaging.
-
"Nature": Sequencing technology has made important progress, refreshing the understanding of cancer and aging
Time of Update: 2021-05-21
Robert Osborne, who was responsible for developing this method, pointed out that the improved accuracy of single-cell sequencing allowed scientists to achieve the first Research on DNA changes in human tissues.
-
What kind of tumor is so dangerous that it will fill the liver in two weeks...
Time of Update: 2021-05-21
The pathological results of the liver biopsy suggest that it is a malignant tumor, which looks like a small cell carcinoma, and needs to be further confirmed by immunohistochemistry.
The patient is suffering from a rare esophageal malignant tumor with a high degree of malignancy, primary esophageal small cell carcinoma (PESC).
-
CDK inhibitors and immunotherapy work together to save recurrent breast cancer
Time of Update: 2021-05-21
Recently, researchers from the Ohio State University Comprehensive Cancer Center published a new research report titled Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors in Cell Reports, and found that cyclins Dependent kinase (CDK) inhibitors can significantly improve the immunotherapy effect of recurrent breast cancer.
-
Why do some cancer cells prefer to metastasize to the bones?
Time of Update: 2021-05-21
▲The metabolic pathway mediated by EZH2 in the bone microenvironment affects ER signal expression and produces tolerance to endocrine therapy (picture source: reference [2]) It is worth noting that the interaction with osteoblasts also triggers Changes in gene expression make cancer cells have stem cell-like characteristics, such as uncontrolled self-renewal and differentiation into various cell types.
-
NGS protocol and clinical application of multiple myeloma
Time of Update: 2021-05-21
Multiple myeloma-Landscape 2018 published a study NGS detection template included a total of 246 genes, a total of 215 genes were detected to have mutations in 418 patients, of which 106 are clear oncogenes, and the possible oncogenes are 71.
-
JAMA Oncol: Both advanced molecular thyroid tests can reduce the need for diagnostic surgery
Time of Update: 2021-05-20
A new study compares the performance characteristics of RNA testing and DNA RNA testing to predict the risk of malignancy for approximately 20% of thyroid nodules that show uncertain fine-needle aspiration (FNA) cytology results.
-
Lancet Oncol: Ipilimumab combined with anti-PD-1 therapy significantly improved the clinical prognosis of patients with advanced melanoma resistant to PD-1
Time of Update: 2021-05-20
Two reported grade 3-5 adverse events similar proportion of patients with immuneTo sum up, in patients with melanoma who are resistant to anti-PD-(L)1 therapy, the efficacy of ipilimumab combined with anti-PD-1 therapy is significantly higher than that of ipilimumab monotherapy, which not only improves the objective remission rate, but also Both progression-free survival and overall survival were significantly prolonged .
